Mayne Pharma Group Ltd
ASX:MYX
Mayne Pharma Group Ltd
Mayne Pharma Group Ltd. engages in the development and manufacture of proprietary and generic products. The company is headquartered in Adelaide, South Australia. The company went IPO on 2007-06-29. The Company’s segments include Generic Products (GPD), Specialty Products (SPD), Metrics Contract Services (MCS), and Mayne Pharma International (MPI). The GPD segment is engaged in the distribution of generic pharmaceutical products in the United States. GPD segment engaged in the distribution of generic pharmaceutical products in the United States. MCS segment is providing contract pharmaceutical development and manufacturing services to third party customers principally in the United States. SPD segment is distributing specialty pharmaceutical products in the United States. MPI segment manufactures and sells branded and generic pharmaceutical products globally and provisions of contract manufacturing services to third party customers within Australia.
Mayne Pharma Group Ltd. engages in the development and manufacture of proprietary and generic products. The company is headquartered in Adelaide, South Australia. The company went IPO on 2007-06-29. The Company’s segments include Generic Products (GPD), Specialty Products (SPD), Metrics Contract Services (MCS), and Mayne Pharma International (MPI). The GPD segment is engaged in the distribution of generic pharmaceutical products in the United States. GPD segment engaged in the distribution of generic pharmaceutical products in the United States. MCS segment is providing contract pharmaceutical development and manufacturing services to third party customers principally in the United States. SPD segment is distributing specialty pharmaceutical products in the United States. MPI segment manufactures and sells branded and generic pharmaceutical products globally and provisions of contract manufacturing services to third party customers within Australia.
Leadership Change: Mayne Pharma announced a planned CEO transition, with Aaron Gray taking over from Shawn O'Brien as of February 21, ensuring strategy and operational continuity.
Stable Revenue: Revenue for 1H fiscal '26 was $212.1 million, essentially flat versus the prior year, despite solid prescription growth, particularly in Women's Health.
Margin Expansion: Gross margin improved to 65.3%, up from 61.4%, driven by favorable portfolio mix, especially in Dermatology.
EBITDA Impacted: Underlying EBITDA declined by 8% to $28.6 million, mainly due to intentional sales investments and elevated legal and transaction costs.
Cash Position: The company remains cash generative, closing the half with $67.3 million in cash and marketable securities, despite significant one-off payments.
Segment Dynamics: Dermatology delivered strong margin and contribution growth despite lower revenue, while Women's Health saw broad-based demand growth but was impacted by product returns and higher operating expenses.
Outlook: The company targets continued growth through focused investments, portfolio expansion, and capital allocation initiatives, with efforts underway to address product returns and to defend intellectual property.
